Kyowa Kirin affirms commitment to developing rocatinlimab as a life-changing differentiated asset with significant market ...

Amgen ends its rocatinlimab partnership, returning control to Kyowa Kirin, citing strategy changes, weaker Phase 3 results ...

Experts discuss the importance of balancing effective symptom control with quality of life in managing chronic pediatric atopic dermatitis, emphasizing personalized treatment plans that address both ...

Topline data were announced from two phase 3 trials evaluating amlitelimab for the treatment of moderate to severe atopic dermatitis.

Amgen and Kyowa Kirin are pulling the plug on a collaboration the drugmakers launched in 2021 aimed at developing a treatment for the inflammatory skin disease atopic dermatitis.

A cohort study finds the risk for acne in patients on JAK inhibitors for atopic dermatitis was about 2.5 times greater than ...

Sanofi has announced that its amlitelimab has shown positive results in the treatment of patients 12 years and older with ...

Lawrence Eichenfield, MD, outlines a patient-centered approach to atopic dermatitis, assessing disease history, life impact, and prior therapy use.

Atopic dermatitis (AD) is a chronic disease that affects an increasing number of children and adults. The skin is dry and ...

The global atopic dermatitis market size was valued at USD 6.62 billion in 2025 and is predicted to hit around USD 12.97 billion by 2034, rising at a 7.75% CAGR, a study published by Towards ...

If you’re a person of color, finding the right treatment for atopic dermatitis, a common form of eczema, can be challenging. Even though the disease is more prevalent in Black Americans than white ...

"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this journey through a disease state contains ...